Biohaven Pharmaceutical Holding Company Ltd. (BHVN) |
|
62.27 -0.42 (-0.67%)
|
09-29 00:32 |
|
Open: |
63.21 |
Pre. Close: |
62.69 |
|
High:
|
63.98 |
Low:
|
61.95 |
|
Volume:
|
350,077 |
Market Cap:
|
3,717M |
|
|
|
|
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. The company is headquartered in New Haven, Connecticut and currently employs 63 full-time employees. The firm is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The firm's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
64.074 - 64.397 |
64.397 - 64.663 |
|
Low:
|
61.233 - 61.57 |
61.57 - 61.848 |
|
Close:
|
61.796 - 62.325 |
62.325 - 62.759 |
|
Technical analysis |
as of: 2020-09-28 4:30:20 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 76.15  One year: 88.95 |
| Support: |
Support1: 60.56 Support2: 57.70 |
| Resistance: |
Resistance1: 65.20 Resistance2: 76.15 |
| Pivot: |
62.07 |
| Moving Average: |
MA(5): 62.51  MA(20): 62.08
MA(100): 64.21 MA(250): 53.53 |
| MACD: |
MACD(12,26): -0.25 Signal(9): -0.49 |
| Stochastic oscillator: |
%K(14,3): 62.80 %D(3): 64.86 |
| RSI: |
RSI(14): 49.33 |
| 52-week: |
High: 78.75 Low: 26.56 Change(%): 50.4 |
| Average Vol(K): |
3-Month: 50987 10-Days: 58171 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.BHVN has closed below upper band by 45.6%. Bollinger Bands are 55.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to BHVN's normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Mon, 28 Sep 2020
BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region - PRNewswire
Sat, 26 Sep 2020
Investor confidence returns after Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) share prices gain $0.44 - Marketing Sentinel
Thu, 24 Sep 2020
Should Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock be in Your Portfolio? - InvestorsObserver
Thu, 24 Sep 2020
Daily High to Daily Low: Is It Safe to Buy Biohaven Pharmaceutical Holding Company Ltd. (BHVN)? - newsheater.com
Wed, 23 Sep 2020
Should You Buy Biohaven Pharmaceutical Holding Co Ltd (BHVN) Stock After it Has Fallen 0.03% in a Week? - InvestorsObserver
Wed, 23 Sep 2020
John W. Childs Buys 3,322 Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Stock - MarketBeat
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Underperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Underperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
58 |
| Shares Float (M) |
52 |
|
% Held by Insiders
|
13.91 |
|
% Held by Institutions
|
97.21 |
|
Shares Short (K)
|
9,570 |
|
Shares Short P. Month (K)
|
9,320 |
Stock Financials |
|
EPS
|
-11.100 |
|
EPS Est This Year
|
-5.450 |
|
EPS Est Next Year
|
-4.390 |
|
Book Value (p.s.)
|
-0.600 |
|
Profit Margin
|
|
|
Operating Margin
|
-4949.62 |
|
Return on Assets (ttm)
|
-73.3 |
|
Return on Equity (ttm)
|
-805.5 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
0.186 |
|
EBITDA (p.s.)
|
-9.187 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-497 |
|
Levered Free Cash Flow (M)
|
-341 |
Stock Valuations |
|
PE Ratio
|
-5.61 |
|
PEG Ratio
|
|
|
Price to Book value
|
-103.82 |
|
Price to Sales
|
334.64 |
|
Price to Cash Flow
|
-7.30 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
